EP Patent

EP3096756B1 — Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia

Assigned to Neurocrine Biosciences Inc · Expires 2024-06-12 · 2y expired

What this patent protects

Patent listed against Crenessity.

Drugs covered by this patent

Patent Metadata

Patent number
EP3096756B1
Jurisdiction
EP
Classification
—
Expires
2024-06-12
Drug substance claim
No
Drug product claim
No
Assignee
Neurocrine Biosciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.